EA
REGN icon

Enclave Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Enclave Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-457
Closed -$240K – 125
2025
Q2 		$240K Sell
457
-31
-6% -$17.3K 0.04% 109
2025
Q1 		$310K Buy
488
+96
+24% +$66K 0.05% 93
2024
Q4 		$279K Buy
392
+94
+32% +$78.9K 0.05% 103
2024
Q3 		$313K Buy
+298
New +$332K 0.05% 96

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Enclave Advisors's REGN Position: Q3 2025 in Review

Enclave Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 457 shares — an estimated $240K sold.

Enclave Advisors first reported a position in REGN in Q3 2024 and held it in 4 quarters. The position peaked at $313K in Q3 2024. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Enclave Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Enclave Advisors sold 457 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $240K.
  • Enclave Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Enclave Advisors's Regeneron Pharmaceuticals position peaked at $313K in Q3 2024.
  • 1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Enclave Advisors's 13F filing for Q3 2025, filed 15 Oct 2025.